Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neoadjuvant Nivolumab for Operable Esophageal Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03987815
Recruitment Status : Not yet recruiting
First Posted : June 17, 2019
Last Update Posted : June 17, 2019
Sponsor:
Collaborator:
Ono Pharmaceutical Co. Ltd
Information provided by (Responsible Party):
Samsung Medical Center

Tracking Information
First Submitted Date  ICMJE June 12, 2019
First Posted Date  ICMJE June 17, 2019
Last Update Posted Date June 17, 2019
Estimated Study Start Date  ICMJE August 1, 2019
Estimated Primary Completion Date July 31, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 12, 2019)
Major pathologic response [ Time Frame: 2 months ]
Viable tumor comprised ≤ 10% of resected tumor specimens
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: June 12, 2019)
  • Objective response rate (ORR) [ Time Frame: 2 months ]
    Partial response is defined as a decrease by 30% or more in sums of longest diameter of measurable target lesions
  • Positron Emission Tomography (PET)-CT response [ Time Frame: 2 months ]
    Complete metabolic response is defined as the SUV of 2.5 or less than 2.5 of primary tumor
  • Progression-free survival (PFS) [ Time Frame: 24 months ]
    Time from the enrollment to disease relapse after complete resection or death from any cause
  • Overall survival (OS) [ Time Frame: 24 months ]
    Time from the enrollment to death of any cause
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Neoadjuvant Nivolumab for Operable Esophageal Carcinoma
Official Title  ICMJE Neoadjuvant Nivolumab for Operable Esophageal Squamous Cell Carcinoma
Brief Summary This is a single arm phase II study, in which maximum 3 cycles of nivolumab (240 mg fixed dose every 2 weeks) is administered for T2- or T3-node negative esophageal squamous cell carcinoma, before curative operation.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Esophageal Squamous Cell Carcinoma
Intervention  ICMJE Drug: Nivolumab
Nivolumab
Study Arms  ICMJE Experimental: Study Arm
Nivolumab 240 mg fixed dose every 2 weeks, for maximum of 3 cycles
Intervention: Drug: Nivolumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: June 12, 2019)
20
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 31, 2021
Estimated Primary Completion Date July 31, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Histologically confirmed esophageal squamous cell carcinoma
  2. Clinical stage T2N0 (invasion to muscularis propria) or T3N0 (invasion to adventitia)
  3. ECOG performance 0 or 1
  4. Age 19 years or older

Exclusion Criteria:

  1. Prior therapy (operation, radiotherapy, immunotherapy, or chemotherapy) for esophageal cancer
  2. Ineligibility or contraindication for esophagectomy
  3. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
  4. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
  5. Has severe hypersensitivity and adverse events (≥Grade 3) to nivolumab and/or any PD-1/PD-L1 inhibitors.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 19 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Jong-Mu Sun, Ph.D, MD 82-2-3410-3459 jongmu.sun@samsung.com
Listed Location Countries  ICMJE Korea, Republic of
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03987815
Other Study ID Numbers  ICMJE 2019-01-147-0004
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Samsung Medical Center
Study Sponsor  ICMJE Samsung Medical Center
Collaborators  ICMJE Ono Pharmaceutical Co. Ltd
Investigators  ICMJE
Principal Investigator: Jong-Mu Sun Samsung Medical Center
PRS Account Samsung Medical Center
Verification Date June 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP